학술논문

Updated Phase 1 results from the PYNNACLE Phase 1/2 study of PC14586, a selective p53 reactivator, in patients with advanced solid tumors harboring a TP53 Y220C mutation
Document Type
Journal
Source
MOLECULAR CANCER THERAPEUTICS; DEC 2023, 22 12, 2p. Supplement: S
Subject
Language
English
ISSN
15388514